Intergroupe Francophone de Cancerologie Thoracique
Afatinib(Intergroupe Francophone de Cancerologie Thoracique)은 FRα 표적 치료제로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregu. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 12% (ClinicalTrials.gov NCT02115048). PK: t½ 37 h. 차별점: Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.
FRα
Non Small Cell Lung Cancer
Discontinued
bispecific antibody, has shown promising efficacy in advanced lung can
Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice
Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling
immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in ad
apoptosis of LUAD cells was significantly increased (P < 0
HER2 kinase inhibitor that the FDA, has approved for the treatment of HER2-positive
resistance mechanism to lorlatinib]
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Intergroupe Francophone de Cancerologie Thoracique
Afatinib(Intergroupe Francophone de Cancerologie Thoracique)은 FRα 표적 치료제로, Non Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregu. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 12% (ClinicalTrials.gov NCT02115048). PK: t½ 37 h. 차별점: Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.
FRα
Non Small Cell Lung Cancer
Discontinued
bispecific antibody, has shown promising efficacy in advanced lung can
Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice
Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling
immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in ad
apoptosis of LUAD cells was significantly increased (P < 0
HER2 kinase inhibitor that the FDA, has approved for the treatment of HER2-positive
resistance mechanism to lorlatinib]
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.